Competitor Analysis availables at pipeline stores

Newsletters

Weekly newsletter focused on antibodies, proteins & peptides, gene therapy, RNA and cell therapy, vaccines, biogenerics and related business. It contains brief abstracts of preclinical & clinical studies, regulatory updates and company news of the previous week, but for biologics only. Subscribe Now

Consultancy

Need consultancy on this topic? La Merie SL provides consultancy services to all clients who wish a fully personal, individual, strictly confidential and exclusive collaboration on a specific subject.

Interferon

 

Interferon

Competitor Analysis availables at Pipelinereview.com

Need consultancy on this topic?

The Competitive Intelligence Report Interferon as of April 2007 provides a competitor analysis in the development pipelines of interferon alpha and interferon beta projects and of other interferon subtypes and subclasses, mainly for the treatment of chronic hepatitis C and of multiple sclerosis.

The report describes the market size and sales figures of the branded interferon products for 2006 and the challenges imposed by biogenerics (syn.: biosimilar , follow-on biologic , follow-on protein ) and improved next generation interferon projects. Improvement is conferred by engineering of the interferon protein, use of drug delivery technologies enabling longer half-life by slow release formulations or pegylation of the molecule or allowing non-invasive administration such as oral dosing.

Among the companies with first and second generation interferon alpha and beta affected by biogenerics are Schering-Plough, Biogen Idec, Merck Serono, Bayer Schering and Roche. The biogenerics pipeline includes Western companies as well as companies from India , South Korea , China , Argentina and Cuba as the major contribuents of biogeneric proteins. Among these companies are Teva, Bio-Sidus, Glenmark, CJ Corporation many more.

 

Buy now a Competitor Analysis on:
Interferon